Tumor-Targeting with Stimuli-Responsive Vesicular Nanocarriers (eBook, ePUB)

Basics to Emerging Applications
Redaktion: Jain, Ankit; Palakurthi, Srinath; Mody, Nishit

• Format: ePub

Produktbeschreibung

Tumour-Targeting with Stimuli Responsive Vesicular Nanocarriers: Basics to Emerging Applications not only acquaints scientists and science interns with the fundamental knowledge of the experimental aspects and state-of-the-art technology for vesicular carriers to equip their rational application in tumor targeting, but also provides a holistic understanding of regulatory concerns, patents, and clinical trials. In 15 chapters. this book provides basics and advances in stimuli-responsive vesicular carriers for tumor targeting based on findings outlined in highly organized tables, illustrative figures, and flow charts.With a focus on the extrapolation of bioengineering tools in the domain of vesicular carriers, stimuli-responsive features concerning tumors, drug delivery approaches, and associated challenges, it helps readers to define the major gaps in knowledge that can lead to significant scientific discoveries in therapy, diagnosis, and theragnosis of cancer. - Addresses the unmet needs and challenges confronted by nanotechnologists to foster collaboration of biologists, chemists, physicists, bioengineers, and clinicians - Provides an explicit account of vital aspects of PEGylation of these carriers and challenges for effective tumor targeting - Presents a need-of-hour discussion over regulatory concerns, clinical trials, and patents

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 240
• Erscheinungstermin: 15. April 2025
• Englisch
• ISBN-13: 9780443291265
• Artikelnr.: 73888838

Autorenporträt

Dr. Ankit Jain is currently working as a Postdoctoral Research Associate at Texas A&M University School of Pharmacy, Texas. He completed his B. Pharm. (2006-09), M. Pharm. (Pharmaceutics, 2009-11), and Ph.D. (2012-17). Dr. Jain has been exploring different vesicular carriers viz. liposomes, niosomes, and micelles for the last eleven years. He has earmarked an appreciation for his outstanding performance in academics. He has been conferred with the "MP Young Scientist Award- 2017?. He has published 60 International publications in journals of high repute (Citations = 2500+, h-index = 21, and I10-index = 55) along with 25 book chapters in International Books. He is a reviewer and editorial board member of different renowned journals of international publishers An overarching goal of his current research is the development of nano-engineered drug delivery systems for various diseases with a prime focus on cancer

Inhaltsangabe

1. Anomalous tumor microenvironment: exploitable features for drug delivery
2. Vesicular carriers for stimuli-responsive drug delivery to tumors:
design considerations
3. Role of dePEGylation in vesicular carriers mediated stimuli-responsive
drug delivery to tumors
4. pH-responsive vesicular carriers as promising tools for tumor targeting
5. Enzyme-responsive vesicular carriers as an emerging approach for tumor
targeting
6. Redox-responsive vesicular carriers for potential tumor-targeting
applications
7. Hypoxia-responsive vesicular carriers for enhanced tumor targeting
8. Magnetically responsive and thermo-responsive vesicular carriers for
improved drug delivery to tumors
9. Cancer Therapy with Vesicular Drug Delivery System and Ultrasound
Assistance
10. Light-triggered vesicular carriers for tumor targeting
11. Electro- and Mechano-responsive vesicular carriers targeting tumors
12. Emerging applications of stimuli-responsive novel vesicular carriers:
Exosomes, supramolecular vesicles, and catanionic vesicles
13. Vesicular carriers with multipronged features for diagnostics and
theranostics
14. Nanotoxicity and challenges in stimuli-responsive vesicular carriers
targeting tumor
15. Patents, clinical trials, and regulatory concerns with
stimuli-responsive vesicular carriers.